Status:
COMPLETED
A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants
Lead Sponsor:
Pfizer
Conditions:
Respiratory Syncytial Virus Infections
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this clinical trial is to learn about the interaction of sisunatovir with four medications (midazolam, itraconazole, rifampicin, and verapamil). These medications are known to have spec...
Eligibility Criteria
Inclusion
- Age 18 to 45 years, inclusive
- Willing to comply with protocol defined contraception requirements
- In good health with no history of major medical conditions
- A body mass index (BMI) of 18 - 25 kg/m2
Exclusion
- Evidence of any clinically significant or currently active major medical condition
- Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab)
- Not willing to comply with protocol defined restrictions for intake of drugs of abuse, alcohol, nicotine-containing products, medication (prescription, OTC, herbal, vitamins/minerals etc) and specified food and drink products
Key Trial Info
Start Date :
November 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 17 2019
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT03782662
Start Date
November 7 2018
End Date
March 17 2019
Last Update
April 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Richmond Pharmacology Ltd
London, United Kingdom, SE1 1YR